Back

Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Clinical impact of lipid‑lowering strategies Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Michael Koren

ENCORE Research Group, Jacksonville (United States of America)

7 More presentations in this session

Presentation thumbnail
Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
Professor C. Li (Nanjing, CN)
Abstract Slides
Presentation thumbnail
Comparative efficacy of APOC3- and ANGPTL3-targeted therapies in severe hypertriglyceridemia: a systematic review and network meta-analysis
Doctor G. Caldeira Gaelzer (Curitiba, BR)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Quantitative and qualitative lipid responses to lipid-lowering therapy and cardiovascular outcomes after percutaneous coronary intervention for acute myocardial infarction
Doctor K. Lee (Daejeon, KR)
Presentation thumbnail
Treatment with PCSK9 inhibitors reduces the expression of scavenger receptors CD16, CD36 and CD45 in patients with stable coronary artery disease and elevated Lp(a) levels
Doctor S. Ugovsek (Ljubljana, SI)
Abstract Slides

Access the full session

Session thumbnail
Clinical impact of lipid‑lowering strategies

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026
thumbnail
Congress Presentation
Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study
27 August 2021
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources